The U.S. Food and Drug Administration (FDA) has given brain chip maker Neuralink permission to conduct human studies, the company’s press office said.
“We are pleased to announce that we have received FDA approval to launch our first human clinical trial! This is an important first step that will one day allow our technology to help many people,” Neuralink tweeted.
The company clarified that the recruitment of people to participate in the clinical trial is not yet open, and also promised to provide details later.
Company founder Elon Musk has announced human trials of the chips several times in recent years, but Neuralink only requested FDA approval in early 2022, when the application was rejected.
The management’s decision was due to the fact that the chips had several flaws that needed to be corrected in order to obtain permission. According to agency sources, the main problems were related to the battery, the ability of the implant wires to migrate inside the brain, and the safe removal of the device.
Elon Musk created Neuralink in 2016. In 2019, the company introduced a prototype of a chip implanted in the brain. As the main goal of Neuralink, Elon Musk called the creation of a brain-computer interface in order to allow people to eliminate the consequences of brain and spinal cord injuries in the future. In addition, writes Reuters, Musk believes that brain implants can help people with various problems, including obesity and depression.
Source: GOROD.LV – новости Даугавпилса by gorod.lv.
*The article has been translated based on the content of GOROD.LV – новости Даугавпилса by gorod.lv. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!
